Calvert Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Calvert Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,847	Closed	-$419K	–	304
2016 Q4	$419K	Sell	3,847 -35	-0.9%	-$3.9K	0.02%	581
2016 Q3	$472K	Buy	3,882 +190	+5%	+$25.6K	0.02%	545
2016 Q2	$522K	Buy	+3,692	New	+$544K	0.02%	493
2015 Q2	–	Sell	-2,659	Closed	-$459K	–	658
2015 Q1	$459K	Buy	2,659 +280	+12%	+$48.1K	0.03%	375
2014 Q4	$390K	Buy	2,379 +168	+8%	+$27.9K	0.03%	389
2014 Q3	$355K	Buy	+2,211	New	+$340K	0.03%	399

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Calvert Investment Management's JAZZ Position: Q1 2017 in Review

Calvert Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2017, closing a stake of 3,847 shares — an estimated $419K sold.

Calvert Investment Management first reported a position in JAZZ in Q3 2014 and held it in 6 quarters. The position peaked at $522K in Q2 2016. 306 funds tracked by Wall St. Rank hold JAZZ as of Q1 2017.

Calvert Investment Management reported no remaining Jazz Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Calvert Investment Management sold 3,847 Jazz Pharmaceuticals shares in Q1 2017, an estimated $419K.
Calvert Investment Management first reported a position in Jazz Pharmaceuticals in Q3 2014 and held it in 6 quarters.
Calvert Investment Management's Jazz Pharmaceuticals position peaked at $522K in Q2 2016.
306 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2017.

Based on Calvert Investment Management's 13F filing for Q1 2017.